JP2016521710A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016521710A5 JP2016521710A5 JP2016518012A JP2016518012A JP2016521710A5 JP 2016521710 A5 JP2016521710 A5 JP 2016521710A5 JP 2016518012 A JP2016518012 A JP 2016518012A JP 2016518012 A JP2016518012 A JP 2016518012A JP 2016521710 A5 JP2016521710 A5 JP 2016521710A5
- Authority
- JP
- Japan
- Prior art keywords
- aryl
- heteroaryl
- cycloalkyl
- alkyl
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003118 aryl group Chemical group 0.000 claims 48
- 125000001072 heteroaryl group Chemical group 0.000 claims 48
- 239000000203 mixture Substances 0.000 claims 41
- 150000001875 compounds Chemical class 0.000 claims 40
- 125000000753 cycloalkyl group Chemical group 0.000 claims 38
- 125000000217 alkyl group Chemical group 0.000 claims 37
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 24
- 125000000623 heterocyclic group Chemical group 0.000 claims 22
- 125000001188 haloalkyl group Chemical group 0.000 claims 17
- 229910052757 nitrogen Inorganic materials 0.000 claims 12
- 206010016654 Fibrosis Diseases 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 230000004761 fibrosis Effects 0.000 claims 8
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 7
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 7
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 150000001204 N-oxides Chemical class 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 239000002207 metabolite Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 2
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 150000001540 azides Chemical class 0.000 claims 2
- 125000004452 carbocyclyl group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
- 150000002825 nitriles Chemical class 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 claims 1
- 230000009787 cardiac fibrosis Effects 0.000 claims 1
- 208000011379 keloid formation Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
- 0 CCC(C)N(C12CC1)C=NC2=*c(cc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC1*C(C*2N=C(C=CC=C3)C3=N2)(C(C=CC(C)C2)=C2F)OC1 Chemical compound CCC(C)N(C12CC1)C=NC2=*c(cc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC1*C(C*2N=C(C=CC=C3)C3=N2)(C(C=CC(C)C2)=C2F)OC1 0.000 description 9
- QNDXGVVJTUSTQB-UHFFFAOYSA-N CC(C(C)O)N(C1=O)N=CN1c(cc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC1OC(CCC2N=CC=NC2)(c(ccc(Cl)c2)c2Cl)OC1 Chemical compound CC(C(C)O)N(C1=O)N=CN1c(cc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC1OC(CCC2N=CC=NC2)(c(ccc(Cl)c2)c2Cl)OC1 QNDXGVVJTUSTQB-UHFFFAOYSA-N 0.000 description 1
- YPAYQJKUDLACIV-UHFFFAOYSA-N CCC(C)C(C1=O)N=CN1c(nc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC1OC(C[n]2nccn2)(c(ccc(C2[IH]C2)c2)c2Cl)OC1 Chemical compound CCC(C)C(C1=O)N=CN1c(nc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC1OC(C[n]2nccn2)(c(ccc(C2[IH]C2)c2)c2Cl)OC1 YPAYQJKUDLACIV-UHFFFAOYSA-N 0.000 description 1
- ASWUIZFNLVGPAW-YDEBFSDOSA-N CCC(C)N(C(C1)=O)N=C[C@H]1[C@H](C)c(cc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC1OC(CC2N=CC=NC2)(c(ccc(I)c2)c2Cl)OC1 Chemical compound CCC(C)N(C(C1)=O)N=C[C@H]1[C@H](C)c(cc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC1OC(CC2N=CC=NC2)(c(ccc(I)c2)c2Cl)OC1 ASWUIZFNLVGPAW-YDEBFSDOSA-N 0.000 description 1
- QDWFDNZETTWLSB-UHFFFAOYSA-N CCC(C)N(C1=C=O)N=CN1c(cc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC1OC(C[n]2c(cccc3)c3nc2)(c(ccc(Cl)c2)c2Cl)OC1 Chemical compound CCC(C)N(C1=C=O)N=CN1c(cc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC1OC(C[n]2c(cccc3)c3nc2)(c(ccc(Cl)c2)c2Cl)OC1 QDWFDNZETTWLSB-UHFFFAOYSA-N 0.000 description 1
- ZOGDGJPWNNBENZ-LTYZHWICSA-N CCCN(CC/C=C(\C)/c(cc1)ccc1OCC1OC(Cc2ccncc2)(c(ccc(Cl)c2)c2Cl)OC1)c1ccc(CC(C=NN2C(C)CC)=CC2=O)cc1 Chemical compound CCCN(CC/C=C(\C)/c(cc1)ccc1OCC1OC(Cc2ccncc2)(c(ccc(Cl)c2)c2Cl)OC1)c1ccc(CC(C=NN2C(C)CC)=CC2=O)cc1 ZOGDGJPWNNBENZ-LTYZHWICSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361832768P | 2013-06-07 | 2013-06-07 | |
| US61/832,768 | 2013-06-07 | ||
| PCT/US2014/041174 WO2014197738A1 (en) | 2013-06-07 | 2014-06-05 | Small molecule inhibitors of fibrosis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016521710A JP2016521710A (ja) | 2016-07-25 |
| JP2016521710A5 true JP2016521710A5 (enExample) | 2017-01-26 |
| JP6414831B2 JP6414831B2 (ja) | 2018-10-31 |
Family
ID=52008597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016518012A Active JP6414831B2 (ja) | 2013-06-07 | 2014-06-05 | 繊維症の小分子阻害剤 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US9663499B2 (enExample) |
| EP (2) | EP3626242B1 (enExample) |
| JP (1) | JP6414831B2 (enExample) |
| KR (1) | KR102240329B1 (enExample) |
| CN (1) | CN105392364B (enExample) |
| AU (1) | AU2014274830B2 (enExample) |
| BR (1) | BR112015030203A2 (enExample) |
| CA (1) | CA2913634C (enExample) |
| CL (1) | CL2015003569A1 (enExample) |
| DK (1) | DK3003038T3 (enExample) |
| EA (1) | EA201592157A1 (enExample) |
| ES (2) | ES2755125T3 (enExample) |
| HK (1) | HK1221606A1 (enExample) |
| MX (1) | MX2015016783A (enExample) |
| PE (1) | PE20160523A1 (enExample) |
| PL (1) | PL3003038T3 (enExample) |
| PT (1) | PT3003038T (enExample) |
| SG (1) | SG11201510011VA (enExample) |
| TN (1) | TN2015000519A1 (enExample) |
| WO (1) | WO2014197738A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4008327A1 (en) | 2009-04-29 | 2022-06-08 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| EP3318255B1 (en) | 2009-06-15 | 2021-03-10 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating stroke in a subject on concomitant statin therapy |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| NZ757815A (en) | 2010-11-29 | 2020-05-29 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US9192609B2 (en) | 2013-04-17 | 2015-11-24 | Hedgepath Pharmaceuticals, Inc. | Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors |
| CA2913634C (en) | 2013-06-07 | 2022-08-09 | The California Institute For Biomedical Research | Small molecule inhibitors of fibrosis |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| CA2968874C (en) * | 2014-12-10 | 2024-06-18 | The California Institute For Biomedical Research | Small molecule inhibitors of fibrosis |
| IL243707A0 (en) | 2016-01-20 | 2016-05-01 | Galmed Res And Dev Ltd | Treatment to regulate the microbiota in the intestine |
| EP3445385A4 (en) | 2016-04-18 | 2019-11-20 | The Trustees of Columbia University in the City of New York | THERAPEUTIC GOALS INVOLVED IN THE PROGRESSION OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) |
| US11197870B2 (en) | 2016-11-10 | 2021-12-14 | Galmed Research And Development Ltd | Treatment for hepatic fibrosis |
| CN106986787A (zh) * | 2017-03-30 | 2017-07-28 | 成都绿林科技有限公司 | 一种泊沙康唑中间体的合成方法 |
| CN106866459A (zh) * | 2017-03-30 | 2017-06-20 | 成都绿林科技有限公司 | 一种抗真菌药物中间体的制备方法 |
| JP2021517558A (ja) * | 2018-03-19 | 2021-07-26 | シェオ ファーマスーティカルズ | 特発性肺線維症を治療するための方法および組成物 |
| KR20210110890A (ko) | 2018-09-24 | 2021-09-09 | 애머린 파마슈티칼스 아일랜드 리미티드 | 대상체에서 심혈관 사건의 위험도를 감소시키는 방법 |
| WO2020081446A1 (en) * | 2018-10-14 | 2020-04-23 | The University Of Chicago | Compositions and methods for activating nrf2-dependent gene expression |
| US12427134B2 (en) | 2019-11-12 | 2025-09-30 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter |
| WO2021207384A1 (en) * | 2020-04-07 | 2021-10-14 | Amarin Pharmaceuticals Ireland Limited | Methods of treating and/or preventing viral infections and/or diseases caused by viruses in a subject in need thereof |
| AU2022263358A1 (en) | 2021-04-21 | 2023-11-30 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4267179A (en) * | 1978-06-23 | 1981-05-12 | Janssen Pharmaceutica, N.V. | Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles |
| US4619931A (en) * | 1983-02-28 | 1986-10-28 | Janssen Pharmaceutica, N.V. | [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles |
| US4791111A (en) | 1985-12-23 | 1988-12-13 | Janssen Pharmaceutica, N.V. | [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles having anti-microbial properties |
| IL103558A0 (en) * | 1991-10-30 | 1993-03-15 | Schering Corp | Tri-substituted tetrahydrofuran antifungals |
| AU683515B2 (en) | 1993-11-19 | 1997-11-13 | Shell Internationale Research Maatschappij B.V. | Polyketone polymer composition |
| US5521186A (en) | 1994-10-27 | 1996-05-28 | Janssen Pharmaceutica N.V. | Apolipoprotein-β synthesis inhibitors |
| US5625064A (en) * | 1995-04-19 | 1997-04-29 | Schering Corporation | Process for the preparation of triazolones |
| TW457240B (en) | 1995-04-20 | 2001-10-01 | Janssen Pharmaceutica Nv | Novel triazolones as apolipoprotein-B synthesis inhibitors |
| EP0957101A1 (en) | 1998-05-14 | 1999-11-17 | Janssen Pharmaceutica N.V. | Water soluble azoles as broad-spectrum antifungals |
| DE60006541D1 (de) | 1999-06-30 | 2003-12-18 | Merck & Co Inc | Src-kinase hemmende verbindungen |
| EP1330448A2 (en) | 2000-06-20 | 2003-07-30 | Atherogenics, Inc. | 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders |
| US7078526B2 (en) | 2002-05-31 | 2006-07-18 | Transform Pharmaceuticals, Inc. | CIS-itraconazole crystalline forms and related processes, pharmaceutical compositions and methods |
| EA017918B1 (ru) | 2007-12-13 | 2013-04-30 | СИЕНА БИОТЕК С.п.А. | Антагонисты пути hedgehog и их терапевтические применения |
| US20100092479A1 (en) | 2008-08-18 | 2010-04-15 | Combinatorx (Singapore) Pte. Ltd. | Compositions and methods for treatment of viral diseases |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| WO2011088404A1 (en) | 2010-01-15 | 2011-07-21 | Infinity Pharmaceuticals , Inc | Treatment of fibrotic conditions using hedgehog inhibitors |
| GB201015079D0 (en) * | 2010-09-10 | 2010-10-27 | Helperby Therapeutics Ltd | Novel use |
| WO2012047762A2 (en) * | 2010-10-08 | 2012-04-12 | Amplyx Pharmaceuticals, Inc. | Antifungal agents |
| PT2648726T (pt) | 2010-12-07 | 2018-06-25 | Amira Pharmaceuticals Inc | Antagonista de lpa1 policíclico e utilizações do mesmo |
| WO2013036866A1 (en) * | 2011-09-07 | 2013-03-14 | The Johns Hopkins University | Itraconazole analogs and use thereof |
| WO2013106485A2 (en) | 2012-01-09 | 2013-07-18 | The Scripps Research Institute | Ultralong complementarity determining regions and uses thereof |
| JP6133431B2 (ja) | 2012-11-24 | 2017-05-24 | ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． | 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用 |
| CA2913634C (en) | 2013-06-07 | 2022-08-09 | The California Institute For Biomedical Research | Small molecule inhibitors of fibrosis |
| EP3004106B1 (en) | 2013-06-07 | 2017-08-30 | Rhizen Pharmaceuticals S.A. | Dual selective pi3 delta and gamma kinase inhibitors |
-
2014
- 2014-06-05 CA CA2913634A patent/CA2913634C/en active Active
- 2014-06-05 PE PE2015002576A patent/PE20160523A1/es not_active Application Discontinuation
- 2014-06-05 AU AU2014274830A patent/AU2014274830B2/en active Active
- 2014-06-05 JP JP2016518012A patent/JP6414831B2/ja active Active
- 2014-06-05 ES ES14807059T patent/ES2755125T3/es active Active
- 2014-06-05 KR KR1020157036822A patent/KR102240329B1/ko active Active
- 2014-06-05 SG SG11201510011VA patent/SG11201510011VA/en unknown
- 2014-06-05 HK HK16109962.7A patent/HK1221606A1/zh unknown
- 2014-06-05 BR BR112015030203A patent/BR112015030203A2/pt not_active IP Right Cessation
- 2014-06-05 MX MX2015016783A patent/MX2015016783A/es unknown
- 2014-06-05 PT PT148070592T patent/PT3003038T/pt unknown
- 2014-06-05 PL PL14807059T patent/PL3003038T3/pl unknown
- 2014-06-05 TN TN2015000519A patent/TN2015000519A1/en unknown
- 2014-06-05 EP EP19191562.8A patent/EP3626242B1/en active Active
- 2014-06-05 US US14/895,813 patent/US9663499B2/en active Active
- 2014-06-05 WO PCT/US2014/041174 patent/WO2014197738A1/en not_active Ceased
- 2014-06-05 EA EA201592157A patent/EA201592157A1/ru unknown
- 2014-06-05 DK DK14807059T patent/DK3003038T3/da active
- 2014-06-05 CN CN201480032411.7A patent/CN105392364B/zh active Active
- 2014-06-05 ES ES19191562T patent/ES2991873T3/es active Active
- 2014-06-05 EP EP14807059.2A patent/EP3003038B1/en active Active
-
2015
- 2015-12-07 CL CL2015003569A patent/CL2015003569A1/es unknown
-
2017
- 2017-04-14 US US15/488,206 patent/US9981956B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016521710A5 (enExample) | ||
| HRP20200538T1 (hr) | Derivati pirimidina za liječenje virusnih infekcija | |
| JP2017504635A5 (enExample) | ||
| JP2016196492A5 (enExample) | ||
| JP2016500661A5 (enExample) | ||
| JP2015514806A5 (enExample) | ||
| JP2017509689A5 (enExample) | ||
| ME02838B (me) | 3,4-dihidroizokinolin-2(1h)-ilni spojevi | |
| NZ610151A (en) | Salts and crystalline forms of an apoptosis-inducing agent | |
| JP2017508782A5 (enExample) | ||
| JP2016525075A5 (enExample) | ||
| JP2011252024A5 (enExample) | ||
| JP2017511357A5 (enExample) | ||
| JP2016514159A5 (enExample) | ||
| JP2017535614A5 (enExample) | ||
| JP2014506599A5 (enExample) | ||
| JP2016512520A5 (enExample) | ||
| JP2015514808A5 (enExample) | ||
| JP2015537008A5 (enExample) | ||
| JP2014520767A5 (enExample) | ||
| JP2013531074A5 (enExample) | ||
| JP2017538769A5 (enExample) | ||
| JP2017537937A5 (enExample) | ||
| SI3102573T1 (en) | SUBSTITUTED TIAZOL OR OXASOL AS ANTAGONISTS OF THE RECEPTOR P2X7 | |
| JP2016512515A5 (enExample) |